Latest Licensing Agreements News

NeuRizer Ltd has advanced its NeuRizer Urea Project with key environmental approvals and construction plans, while raising $350,000 through private placements. However, the company faces a trading suspension as it works to resolve audit and compliance issues with the ASX.

St George Mining has partnered with Spain’s Tecnicas Reunidas to test advanced processing technology on its Araxá rare earths, aiming to unlock European markets alongside existing US and Brazilian alliances.

BrainChip Holdings has inked a global licensing agreement with Korea’s EDGEAI, granting access to its Akida 2 neuromorphic AI technology for EDGEAI’s upcoming semiconductor products. The deal includes milestone payments and royalties, marking a significant step in BrainChip’s global expansion and the growing edge AI market.

Temas Resources has formed a Scientific Advisory Board of hydrometallurgical leaders to accelerate the rollout of its innovative Regenerative Chloride Leaching technology, promising major cost and environmental benefits in critical minerals processing.

Weebit Nano has launched a significant A$80 million institutional placement, alongside additional funding initiatives, to accelerate its ReRAM technology leadership and broaden AI-related offerings.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.

PARKD Limited reported a 37% revenue decline to $3.88 million for H1 FY2026, driven by the winding down of its flagship Audi Centre Myaree project. The company posted a $1.03 million loss as it invests in East Coast growth and commissions a new prefabrication facility in Penrith, NSW.

ClearVue Technologies reported a 9% reduced half-year loss of $5.25 million, while pushing forward with significant advancements in its solar glass technology and expanding global licensing partnerships.

Avecho Biotechnology reported a 9.3% revenue increase alongside a 41.5% rise in net loss for 2025, while progressing its Phase III CBD insomnia trial and securing a significant licensing agreement with Sandoz.

Yowie Group Limited reported a steep 752% increase in its half-year loss to US$4.66 million, amid governance upheaval and impaired loans to its majority shareholder. The company faces ongoing legal and regulatory challenges while pursuing a turnaround.

Weebit Nano Limited has reported a remarkable 8-fold increase in revenue, driven by a landmark licensing agreement with Texas Instruments and significant progress in its ReRAM technology commercialisation.

Percheron Therapeutics reports a 64% reduction in half-year losses to $3.1 million, driven by progress in its licensed immuno-oncology drug HMBD-002 and a strategic pivot away from discontinued assets.